Anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) have dramatically improved outcomes of nonsmall cell lung cancer (NSCLC) patients whose tumors harbor an ALK translocation [1, 2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.